Horizon Discovery Group

Activities: Analysis Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Cell therapy engages stealth mode to target solid tumours

Cell therapies, such as CAR-T cells, have already generated impressive initial response rates in the clinic for patients suffering from haematological (or blood) cancers, but are yet to make a similar impact in patients with solid tumours, notes Emily M. Anderson, PhD, Principal Scientist, Horizon Discovery
Pharmaceutical

Horizon Discovery expands cell-based CRISPR screening services

Cell line engineering specialist has expanded its range to complement its T cell screening service ­
Manufacturing

Horizon exclusively licenses new base editing technology

Rutgers technology has been incorporated into Horizon Discovery Group’s next-generation gene editing platform
Manufacturing

Horizon Discovery expands CRISPR gene editing portfolio

Gene editing specialist Horizon Discovery has added predesigned synthetic sgRNAs to its offering to streamline CRISPR gene editing workflows
Pharmaceutical

Horizon signs license agreement with Glenmark for CHO cell line

gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line has been licenced to be incorporated into the biomanufacturing process
Manufacturing

Global alliance chooses Horizon Discovery cell line for Zika antibody

Batavia Biosciences, Vanderbilt University Medical Center (VUMC) and IDBiologics will use the cell line expression system to produce and antibody for the potent virus
Recruitment

Horizon Discovery appoints CEO
Subscribe now